Insys Therapeutics Company Profile (NASDAQ:INSY)

About Insys Therapeutics (NASDAQ:INSY)

Insys Therapeutics logoInsys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company's product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue. The Company markets Subsys through its field sales force focused on supportive care physicians in the United States. Subsys delivers a liquid fentanyl formulation in approximately 100, 200, 400, 600, 800, 1,200 and 1,600 micrograms (mcg) dosages. The Company's lead dronabinol product candidate is Syndros, which is under review for approval at the Food and Drug Administration. In addition, the Company is evaluating sublingual spray, inhaled and intravenous formulations of dronabinol in preclinical studies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INSY
  • CUSIP: N/A
  • Web:
  • Market Cap: $864.06 million
  • Outstanding Shares: 72,125,000
Average Prices:
  • 50 Day Moving Avg: $12.42
  • 200 Day Moving Avg: $11.43
  • 52 Week Range: $8.70 - $19.96
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.70
  • P/E Growth: -0.92
Sales & Book Value:
  • Annual Revenue: $217.82 million
  • Price / Sales: 4.04
  • Book Value: $3.71 per share
  • Price / Book: 3.29
  • EBIDTA: $3.16 million
  • Net Margins: -2.64%
  • Return on Equity: -0.97%
  • Return on Assets: -0.75%
  • Current Ratio: 3.18%
  • Quick Ratio: 2.84%
  • Average Volume: 590,146 shs.
  • Beta: 0.88
  • Short Ratio: 13.58
Frequently Asked Questions for Insys Therapeutics (NASDAQ:INSY)

What is Insys Therapeutics' stock symbol?

Insys Therapeutics trades on the NASDAQ under the ticker symbol "INSY."

When did Insys Therapeutics' stock split? How did Insys Therapeutics' stock split work?

Insys Therapeutics shares split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly minted shares were payable to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of Insys Therapeutics stock prior to the split would have 150 shares after the split.

How were Insys Therapeutics' earnings last quarter?

Insys Therapeutics, Inc. (NASDAQ:INSY) released its earnings results on Tuesday, May, 9th. The company reported ($0.09) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.01. The business had revenue of $35.92 million for the quarter, compared to analyst estimates of $37.78 million. Insys Therapeutics had a negative return on equity of 0.97% and a negative net margin of 2.64%. The firm's revenue for the quarter was down 40.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.11 EPS. View Insys Therapeutics' Earnings History.

Where is Insys Therapeutics' stock going? Where will Insys Therapeutics' stock price be in 2017?

4 analysts have issued 12 month price objectives for Insys Therapeutics' stock. Their predictions range from $10.00 to $16.00. On average, they expect Insys Therapeutics' stock price to reach $13.33 in the next twelve months. View Analyst Ratings for Insys Therapeutics.

Who are some of Insys Therapeutics' key competitors?

Who are Insys Therapeutics' key executives?

Insys Therapeutics' management team includes the folowing people:

  • Steven J. Meyer, Chairman of the Board
  • Saeed Motahari, President, Chief Executive Officer, Director
  • Darryl S. Baker, Chief Financial Officer
  • Franc Del Fosse, General Counsel, Corporate Secretary
  • Michael L. Babich, Director
  • John N. Kapoor Ph.D., Director
  • Rohit Vishnoi, Director
  • Patrick P. Fourteau, Independent Director
  • Pierre Lapalme, Independent Director

Who owns Insys Therapeutics stock?

Insys Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Eqis Capital Management Inc. (0.09%). Company insiders that own Insys Therapeutics stock include Daniel Brennan, John N Kapoor Trust Dated Sept, Patrick Fourteau, Rohit Vishnoi, Saeed Motahari, Steven J Meyer and Theodore H Stanley. View Institutional Ownership Trends for Insys Therapeutics.

Who bought Insys Therapeutics stock? Who is buying Insys Therapeutics stock?

Insys Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc.. Company insiders that have bought Insys Therapeutics stock in the last two years include John N Kapoor Trust Dated Sept, Rohit Vishnoi, Saeed Motahari and Steven J Meyer. View Insider Buying and Selling for Insys Therapeutics.

How do I buy Insys Therapeutics stock?

Shares of Insys Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insys Therapeutics' stock price today?

One share of Insys Therapeutics stock can currently be purchased for approximately $12.19.

MarketBeat Community Rating for Insys Therapeutics (NASDAQ INSY)
Community Ranking:  3.1 out of 5 (  )
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about Insys Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Insys Therapeutics (NASDAQ:INSY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.33 (9.38% upside)

Analysts' Ratings History for Insys Therapeutics (NASDAQ:INSY)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/4/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldHighView Rating Details
6/9/2017Jefferies Group LLCReiterated RatingBuy$14.00LowView Rating Details
6/3/2017Royal Bank Of CanadaSet Price TargetBuy$16.00HighView Rating Details
5/10/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$20.00 -> $10.00LowView Rating Details
4/14/2016Janney Montgomery ScottInitiated CoverageBuy$22.00N/AView Rating Details
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$38.00 -> $30.00N/AView Rating Details
(Data available from 7/25/2015 forward)


Earnings History for Insys Therapeutics (NASDAQ:INSY)
Earnings by Quarter for Insys Therapeutics (NASDAQ:INSY)
Earnings History by Quarter for Insys Therapeutics (NASDAQ INSY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.10)($0.09)$37.78 million$35.92 millionViewListenView Earnings Details
4/3/2017Q4 2016$0.00$0.03$52.08 million$54.86 millionViewN/AView Earnings Details
11/3/2016Q316$0.02$0.07$55.97 million$55.20 millionViewN/AView Earnings Details
8/3/2016Q216$0.07$0.06$66.90 million$67.10 millionViewListenView Earnings Details
4/28/2016Q116$0.07$0.11$61.31 million$62.00 millionViewListenView Earnings Details
2/23/2016Q415$0.29$0.36$91.04 million$91.10 millionViewListenView Earnings Details
11/5/2015Q315$0.23$0.50$82.98 million$91.30 millionViewN/AView Earnings Details
8/6/2015Q215$0.21$0.16$74.06 million$77.60 millionViewN/AView Earnings Details
5/7/2015Q115$0.40$0.63$70.90 million$70.80 millionViewN/AView Earnings Details
3/3/2015Q414$0.44$0.53$63.50 million$66.50 millionViewN/AView Earnings Details
11/11/2014Q314$0.29$0.63$57.10 million$58.30 millionViewN/AView Earnings Details
8/12/2014Q214$0.30$0.48$52.77 million$55.70 millionViewN/AView Earnings Details
3/4/2014Q413$0.55$0.71$34.73 million$40.20 millionViewN/AView Earnings Details
11/12/2013Q3$0.33$0.58$27.00 million$29.20 millionViewListenView Earnings Details
8/13/2013Q213$0.12$0.35$15.07 million$18.80 millionViewN/AView Earnings Details
6/3/2013Q113$0.01$2.00 million$11.10 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Insys Therapeutics (NASDAQ:INSY)
Current Year EPS Consensus Estimate: $-0.53 EPS
Next Year EPS Consensus Estimate: $-0.44 EPS


Dividend History for Insys Therapeutics (NASDAQ:INSY)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Insys Therapeutics (NASDAQ:INSY)
Insider Ownership Percentage: 67.90%
Institutional Ownership Percentage: 28.18%
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Institutional Ownership by Quarter for Insys Therapeutics (NASDAQ:INSY)
Insider Trades by Quarter for Insys Therapeutics (NASDAQ:INSY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017Saeed MotahariCEOBuy5,400$11.10$59,940.00View SEC Filing  
6/1/2017Rohit VishnoiDirectorBuy4,000$14.14$56,560.00View SEC Filing  
5/18/2017Steven J MeyerDirectorBuy8,000$12.21$97,680.00View SEC Filing  
5/16/2017Saeed MotahariCEOBuy4,500$11.98$53,910.00View SEC Filing  
11/4/2016Steven J MeyerDirectorBuy10,000$10.75$107,500.00View SEC Filing  
8/16/2016Theodore H StanleyDirectorSell15,000$18.02$270,300.00View SEC Filing  
8/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy5,700$18.57$105,849.00View SEC Filing  
8/11/2016Patrick FourteauDirectorSell15,000$18.46$276,900.00View SEC Filing  
8/9/2016Daniel BrennanVPSell5,781$19.16$110,763.96View SEC Filing  
6/6/2016Theodore H StanleyDirectorSell16,000$16.27$260,320.00View SEC Filing  
5/12/2016John N Kapoor Trust Dated SeptMajor ShareholderBuy50,000$12.84$642,000.00View SEC Filing  
3/4/2016Patrick FourteauDirectorSell15,000$18.22$273,300.00View SEC Filing  
11/17/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy5,000$29.50$147,500.00View SEC Filing  
11/12/2015John N Kapoor Trust Dated SeptMajor ShareholderBuy10,000$26.58$265,800.00View SEC Filing  
11/12/2015Patrick FourteauDirectorSell30,000$26.48$794,400.00View SEC Filing  
9/14/2015Theodore H. StanleyDirectorSell4,000$37.04$148,160.00View SEC Filing  
6/10/2015Fosse Franc DelGeneral CounselSell10,000$34.48$344,800.00View SEC Filing  
6/5/2015Steven J MeyerDirectorSell5,000$63.00$315,000.00View SEC Filing  
5/27/2015Brian TambiDirectorSell3,100$60.09$186,279.00View SEC Filing  
5/26/2015Brian TambiDirectorSell1,800$60.00$108,000.00View SEC Filing  
5/20/2015Patrick FourteauDirectorSell9,064$60.00$543,840.00View SEC Filing  
5/18/2015Darryl S BakerCFOSell10,000$59.17$591,700.00View SEC Filing  
5/11/2015Steven J MeyerDirectorSell18,000$57.06$1,027,080.00View SEC Filing  
3/17/2015Michael L BabichCEOSell75,000$58.63$4,397,250.00View SEC Filing  
3/11/2015Patrick FourteauDirectorSell10,000$59.94$599,400.00View SEC Filing  
3/10/2015Theodore H StanleyDirectorSell3,300$60.03$198,099.00View SEC Filing  
2/9/2015Darryl S BakerCFOSell30,000$52.23$1,566,900.00View SEC Filing  
11/19/2014Patrick FourteauDirectorSell25,000$39.11$977,750.00View SEC Filing  
11/4/2014Michael L BabichCEOSell80,000$38.66$3,092,800.00View SEC Filing  
8/13/2014Theodore H StanleyDirectorBuy3,000$33.93$101,790.00View SEC Filing  
6/16/2014John N KapoorDirectorBuy5,000$26.13$130,650.00View SEC Filing  
6/13/2014John N KapoorDirectorBuy5,000$25.44$127,200.00View SEC Filing  
6/12/2014John N KapoorDirectorBuy20,000$24.84$496,800.00View SEC Filing  
6/11/2014John N KapoorDirectorBuy20,000$24.54$490,800.00View SEC Filing  
5/19/2014Theodore StanleyDirectorBuy4,000$21.94$87,760.00View SEC Filing  
5/15/2014Patrick FourteauDirectorBuy7,500$22.77$170,775.00View SEC Filing  
3/5/2014Larry DillahaInsiderSell149,932$74.57$11,180,429.24View SEC Filing  
3/5/2014Michael BabichCEOSell288,432$74.58$21,511,258.56View SEC Filing  
1/16/2014Darryl BakerCFOSell10,000$49.61$496,100.00View SEC Filing  
1/15/2014Darryl BakerCFOSell10,000$47.54$475,400.00View SEC Filing  
1/14/2014Darryl BakerCFOSell10,000$45.64$456,400.00View SEC Filing  
12/9/2013John KapoorDirectorSell27,428$47.25$1,295,973.00View SEC Filing  
8/16/2013Michael BabichCEOBuy1,000$24.90$24,900.00View SEC Filing  
8/14/2013Patrick FourteauDirectorBuy5,000$23.77$118,850.00View SEC Filing  
6/4/2013Michael L BabichCEOBuy1,250$10.93$13,662.50View SEC Filing  
5/24/2013Pierre LapalmeDirectorBuy3,000$10.39$31,170.00View SEC Filing  
5/14/2013Patrick FourteauDirectorBuy5,000$10.90$54,500.00View SEC Filing  
5/13/2013Patrick FourteauDirectorBuy4,800$10.90$52,320.00View SEC Filing  
5/7/2013Patrick FourteauDirectorBuy50,000$8.36$418,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Insys Therapeutics (NASDAQ:INSY)
Latest Headlines for Insys Therapeutics (NASDAQ:INSY)
DateHeadline logoFBI seizes records tied to Insys-paid doctor in Kansas - Reuters - July 21 at 9:15 PM logoInsys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017 - GlobeNewswire (press release) - July 21 at 4:47 AM logoInsys Therapeutics, Inc. (NASDAQ:INSY) Expected to Post Quarterly Sales of $36.89 Million - July 20 at 11:13 AM logoInsys Therapeutics to Report Second Quarter 2017 Results on August 3, 2017 - July 20 at 8:14 AM logoInsys Therapeutics (INSY) Appoints Andrew Long as CFO - July 19 at 3:43 AM logoInsys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer - July 19 at 3:43 AM logoInsys Therapeutics, Inc. Appoints Andrew G. Long as Chief Financial Officer - Nasdaq - July 18 at 10:39 PM logoETFs with exposure to INSYS Therapeutics, Inc. : July 18, 2017 - July 18 at 10:39 PM logoInsys Therapeutics, Inc. (INSY) Expected to Post Earnings of -$0.10 Per Share - July 18 at 8:20 PM logoInsys Therapeutics, Inc. Releases Statement on Payor Interactions ... - Nasdaq - July 18 at 2:25 AM logoINSYS Therapeutics, Inc. – Value Analysis (NASDAQ:INSY) : July 17, 2017 - July 18 at 2:25 AM logoBRIEF-Insys Therapeutics Inc releases statement on payor interactions - July 17 at 8:24 AM logoInsys Therapeutics, Inc. Releases Statement on Payor Interactions - July 17 at 8:24 AM logoInsys: Anthem Lawsuit Paves The Road For An Equity Raise And Continued Downside Pressure On The Stock - July 16 at 12:01 PM logoHere's the spiel one drug company allegedly used to push its opioids on Americans - July 15 at 2:25 AM logoCannabis Industry Weekly Recap 7/14/2017 - July 15 at 2:25 AM logoAnthem files lawsuit against Insys Therapeutics - Reuters - July 14 at 3:57 AM logoUPDATE 1-Ex-Insys CEO's wife pleads guilty in US to opioid kickback scheme - Reuters - July 13 at 3:20 AM logoEx-Insys saleswomen plead guilty in US to drug kickback schemes - Reuters - July 13 at 3:20 AM
News IconOpioid drugmaker Insys sees guilty pleas and Justice Department ... - Business Insider - July 13 at 3:20 AM logoWhy Barnes & Noble Education, MSC Industrial Direct, and Insys ... - Motley Fool - July 13 at 3:20 AM logoEx-Insys Saleswomen Plead Guilty in Opioid Prescription Kickback Schemes - July 11 at 11:58 PM logoEx-Insys CEO's wife pleads guilty in U.S. to opioid kickback scheme - July 11 at 11:58 PM logoEx-Insys saleswomen plead guilty in U.S. to drug kickback schemes - July 11 at 11:58 PM logo[$$] Ex-Insys Saleswomen Plead Guilty in Opioid Prescription Kickback Schemes - July 11 at 11:58 PM logoEx-Insys employee in US kickback case loses fight to smoke pot - Reuters - July 10 at 7:52 PM logoEx-Insys employee in U.S. kickback case loses fight to smoke pot - July 10 at 7:52 PM logoInsys Therapeutics, Inc. (NASDAQ:INSY) Receives Average Rating of "Hold" from Analysts - July 10 at 9:50 AM logoInsys Therapeutics, Inc. (NASDAQ:INSY) Downgraded by Zacks Investment Research to Sell - July 9 at 1:40 PM logoWill These Be the Top Marijuana Stocks to Own in 2018? - July 9 at 9:26 AM logoInsys Therapeutics, Inc. (NASDAQ:INSY) Raised to Buy at BidaskClub - July 8 at 6:32 PM logoWhy This Marijuana Stock Dropped 11% in June - July 8 at 11:46 AM logoETFs with exposure to INSYS Therapeutics, Inc. : July 7, 2017 - July 8 at 11:46 AM logoInsys Therapeutics, Inc. (INSY) Stock Rating Reaffirmed by Oppenheimer Holdings, Inc. - July 4 at 9:42 PM logoETFs with exposure to INSYS Therapeutics, Inc. : June 26, 2017 - June 26 at 7:45 PM logoInsys Therapeutics, Inc. (INSY) Expected to Post Quarterly Sales of $36.56 Million - June 24 at 8:48 AM logoInsys Therapeutics, Inc. (INSY) Expected to Announce Earnings of -$0.10 Per Share - June 22 at 4:42 PM logoFormer Insys employee pleads guilty in US opioid drug probe - CNBC - June 21 at 3:38 PM logoInsys Therapeutics Hires Four Key Pharmaceutical Industry ... - GlobeNewswire (press release) - June 21 at 4:53 AM logoEx-Insys employee pleads guilty in U.S. opioid drug probe - June 19 at 4:54 PM logoWill SYNDROS Potential Replace SUBSYS Challenges - June 16 at 6:48 PM logoINSYS Therapeutics, Inc. :INSY-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 16 at 6:48 PM logoOpioid Marketing Under Bipartisan Investigation - June 16 at 5:37 AM logoETFs with exposure to INSYS Therapeutics, Inc. : June 15, 2017 - June 16 at 5:37 AM logoInsys Therapeutics, Inc. (INSY) CEO Saeed Motahari Buys 5,400 Shares - June 14 at 8:18 PM logoInsys Therapeutics' Undervalued Cannabis Pipeline - Seeking Alpha - June 14 at 7:55 PM logoInsys: Continued Subsys Fallout As Endo's Painkiller Pulled By FDA - Seeking Alpha - June 12 at 6:33 PM logoINSYS Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : INSY-US : June 12, 2017 - June 12 at 6:33 PM logoINSYS Therapeutics (INSY) Presents At Jefferies 2017 Global Healthcare Conference - Slideshow - June 10 at 10:54 PM logoDepomed, Insys Shares Down After FDA Decision on Endo's Opana ER - June 9 at 8:23 PM



Insys Therapeutics (INSY) Chart for Tuesday, July, 25, 2017

This page was last updated on 7/25/2017 by Staff